Objective: To explore the predictive model of neck central lymph node metastasis in cN0-PTMC patients.SMethods: A total of 1271 cN0-PTMC patients diagnosed by the department of Otolaryngology and Head and Neck Surgery of the First Affiliated Hospital of Xi"an Jiaotong University from 2015 to 2020 were enrolled in this study. According to the surgical records and postoperative pathological results, the clinicopathological data such as age, sex, maximum tumor diameter, tumor location, lateral type, concomitant NG and HT, extraglandular invasion, capsule invasion and neck lymph node metastasis were calculated.SThe correlation between central lymph node metastasis and clinicopathological parameters was analyzed.SResults: the age of 45 years old was used as the classification standard for univariate analysis.SThe results showed that the incidence of CLNM in cN0-PTMC was associated with male, age≤ 45, tumor diameter ≤5mm, concomitant HT and multiple foci (P＜0.05). The incidence of CLNM in cN0-PTMC was not associated with concomitant NG, BRAFV600E gene mutation, tumor location, extraglandular invasion, lateral type and capsule invasion(P＞0.05).SThe categories of P＜0.05 in the univariate analysis were included in the unconditional Logistic regression equation, showed that the risk of CLNM in men with cN0-PTMC was 1.929 times higher than that in women (OR=1.929,95%CI: 1.465-2.541), and the risk of CLNM in patients less than 45 years old was 2.581 times higher than that in those over 45 years old (OR=2.581,95%CI: 2.004-3.324).SThe risk of CLNM in patients with multiple foci was 1.675 times higher than that in patients with single focus (OR=1.675,95%CI: 1.276-2.197), and the risk of CLNM was lower in patients with diameter ≤ 5mm (OR=0.603,95%CI: 0.463-0.785) and with HT (OR=0.642,95%CI: 0.452-0.913).SHT was the risk factor of wild type of BRAFV600E gene in cN0-PTMC patients (OR=3.454,95%CI: 1.865-6.397). Conclusion: male, ≤ 45 years old, > 5mm, without HT and multiple foci are independent risk factors for CLNM in cN0-PTMC patients.SHT is a protective factor for BRAFV600E gene mutation in these patients, and there is no correlation with other clinicopathological features.